NEURO

The novel B-cell therapy has been assigned a PDUFA date of June 2020. from Front page feed https://ift.tt/385zJao

Eptinezumab, Lundbeck’s intravenous monoclonal antibody that will be marketed as Vyepti, will become available for prescription in April 2020 with a recommended dose of 100 mg quarterly. from Front page feed https://ift.tt/2SYEu1k

The lead author of a recent publication from the Memory and Aging Project discussed the data and what impact flavonol intake might have on the risk of developing Alzheimer disease dementia. from Front page feed https://ift.tt/2SGLNtp

This additional application, supported by data from the GWPCARE6 trial, seeks to expand the indication of cannabidiol to include seizures associated with tuberous sclerosis complex. from Front page feed https://ift.tt/2SpLAdW

The software, developed by Qynapse, provides analysis of brain MRI markers in diseases such as Alzheimer disease, Parkinson disease, and multiple sclerosis. from Front page feed https://ift.tt/2S7fNzz

James Leverenz, MD, director of the Lou Ruvo Center for Brain Health at Cleveland Clinic, sat down to discuss the challenges faced in diagnosing Lewy body dementia. from Front page feed https://ift.tt/2qaDHPe

No progressive or delayed complications of treatment were recorded after 3 years in patients with essential tremor who underwent focused ultrasound. from Front page feed https://ift.tt/2On4uB8

SK Life Science’s sodium channel antagonist cenobamate was approved based on data from pivotal trials in nearly 2000 patients in which it reduced the median number of seizures per 28 days. from Front page feed https://ift.tt/35BxLy2

Study data demonstrates that treatment with satralizumab reduces risk of relapses in patients with neuromyelitis optica spectrum disorder. from Front page feed https://ift.tt/3734Uny

The 2019 update to the 2018 guidelines clarifies prior recommendations and takes into consideration new clinical trial data to offer a comprehensive guide for treatment, from symptom onset through 2 weeks after acute ischemic stroke. from Front page feed https://ift.tt/2NZVosL

An 8 year old boy with genetically confirmed neurofibromatosis type 1 presents with first generalized seizure. from Front page feed https://ift.tt/2WWqTb4

The benefits of lowering systolic blood pressure for stroke prevention and reducing poststroke disability are numerous, but the ideal target remains elusive. from Front page feed https://ift.tt/2PX0E32

Treatment with the Catabasis Pharmaceuticals small molecule oral NF-kB inhibitor resulted in improvements in the 10-meter walk/run scores, time-to-stand scores, and 4-stair climb scores in 31 steroid-naïve boys with DMD aged 4 to 7 years. from Front page feed https://ift.tt/2BlgQm4

The latest generic entry comes on the heels of a new report from ICER, which published a list of prescription drugs that had substantial price increases in 2017 and 2018 without what they consider to be new supporting evidence. from Front page feed https://ift.tt/2OTU6Sm

"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Fred Rincon, MD, MSc. from Front page feed https://ift.tt/2VFYFkp

Cerevel Therapeutics’ highly selective dopamine D1/D5 agonist showed significant reductions in UPDRS-III scores for those with early-stage Parkinson disease and is planned to enter phase 3 in 2020. from Front page feed https://ift.tt/331Dvzv

After showing significant benefits in delayed disease progression in patients with secondary progressive MS, new data suggests siponimod can delay the time to wheelchair dependence by 4 years. from Front page feed https://ift.tt/2otjRO2

With a growing emphasis on early detection and intervention, the American Academy of Neurology (AAN) has published a new set of quality measurements that recommend that physicians screen adults 65 and older on an annual basis for thinking and memory problems.1 The metric, intended to help improve quality care, will track how often physicians screen older adults for cognitive impairment, share information about the condition with patients, and involve and educate partners and caregivers. from Front page feed https://ift.tt/2nbxYHw

The phase 3 clinical trial program included 2 identical, multicenter, double-blind, and placebo-controlled trials of the BACE inhibitor intended for the treatment of early Alzheimer disease. from Front page feed https://ift.tt/2I8BeL5

The 1st Annual Congress on the Future of Neurology will take place September 27-28, 2019 at the InterContinental New York Times Square in New York City. from Front page feed https://ift.tt/2UZTFXs